by The Sanford Guide
The 51st edition of the leading clinical reference on treatment of infectious diseases and anti-infective drug information. COVID-19, SARS CoV-2
The Sanford Guide to Antimicrobial Therapy (51st edition)
4.375 x 6.5 inches (Pocket Edition) ISBN: 978-1-944272-16-6
Approximate Font Size: 5.5pt
The 51st edition of the leading clinical reference on treatment of infectious diseases and anti-infective drug information. Helpful in day-to-day practice and as a component of your organization's antimicrobial stewardship program, The Sanford Guide provides valuable guidance in the age of antibiotic resistance. Popular with physicians, pharmacists, physician assistants, nurse practitioners, and other clinicians, The Sanford Guide to Antimicrobial Therapy provides information that is convenient, concise, and reliable.
This year's guide includes a FREE 1-month trial of Sanford Guide All Access, which provides expanded content, interactive tables and tools, updated daily, for mobile apps and the web.
Available in print in pocket size, spiral bound and large library editions.
What's new in 2021:
Updated guidance for dosing vancomycin for severe S. aureus infection (digital trial includes AUC calculator)
Updated information for treatment of gonorrhea to reflect new CDC guidelines
Revised Tables 5B and 5C to reflect current recommendations and options for treatment of highly-resistant infections caused by gram-negative pathogens
Updated treatment options for malaria
Updated monoclonal antibody treatment for Ebola
Revised treatment options for atypical mycobacterial infections
Updated Table 22 covering drug-drug interactions
Numerous other new tables and tools through the included digital trial
4.375 x 6.5 inches (Pocket Edition)
COVID-19, SARS CoV-2
by Editorial Board last updated Sep 5, 2021 9:25 AM © Antimicrobial Therapy, Inc.
Coronavirus, SARS CoV-2, COVID-19
Management of COVID-19
Important Note August 2021:
Other than hypertransmissibility and high peak viral loads, current understanding of SARS-CoV-2 infection with the currently predominant Delta variant, is very limited although improving daily. Delta has many unique properties. Most knowledge of clinical, epidemiologic, therapeutic, and diagnostic aspects of infection and COVID-19 are based on studies done in the pre-Delta era and recommendations based on references that pre-date Delta should be interpreted in that context. Of course, we will continue to update COVID-19 information and recommendations based on new developments.
See COVID-19 Prevention for authorized vaccines and information.
Initial Clinical Evaluation
Symptomatic person with positive test result (PCR or antigen)
Initial clinical evaluation focuses on:
Age > 65 years, immune-compromised state, obesity (BMI >35), diabetes mellitus, chronic kidney disease
Potential treatment-limiting organ dysfunction (renal, hepatic)
Date of onset of symptoms, not date of first positive test (to determine duration of illness)
Severity of disease
Child or adolescent, see also MIS-C / MIS-A
Refs: NIH COVID-19 Treatment Guidelines; N Engl J Med 2020;382:1708; Lancet 2020;395:497; JAMA 2020;323:1061; JAMA 2020;323:1239.